Welcome to Regeneus
Regeneus Ltd (ASX: RGS) is an Australian clinical-stage regenerative medicine company developing a patented portfolio of cell therapies to address significant unmet medical needs in the human and animal health markets with a focus on musculoskeletal disease, oncology and dermatology.
Our technology platform includes 3 major platforms across both our human and animal health businesses:
- Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases;
- Human and animal immunotherapy personalised cancer vaccine for the treatment of a wide variety of cancers; and,
- Stem cell secretions (cell free supernatant) – CFS technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments.
Regeneus’ strategy is to continue to develop innovative technologies partnering with larger companies with commercialisation capabilities to develop and market the products.